Condition
Endogenous Cushing Syndrome
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
Treatment Research
3 treatments under study, led by Osilodrostat
Research Leaders
5 sponsors active, led by RECORDATI GROUP
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 2 (1)
Phase 4 (1)
Trial Status
Recruiting1
Active Not Recruiting1
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT03604198Phase 2Active Not Recruiting
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
NCT06430528RecruitingPrimary
A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement
NCT06131580Phase 4UnknownPrimary
Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's Syndrome
Showing all 3 trials
Research Network
Common Treatments
- Osilodrostat1
- Relacorilant1
- Interventiontreatment1
Active Sponsors
- RECORDATI GROUP2
- Corcept Therapeutics Inc.1
- University of Michigan1
- Centre hospitalier de l'Université de Montréal (CHUM)1
- Corcept Therapeutics1
Top Investigators
University of Michigan
Corcept Therapeutics
Centre hospitalier de l'Université de Montréal (CHUM)
Related Conditions
- Cushing Syndrome1
- Hypercortisolism1
- Adrenal Insufficiency1